Toxicologic Pathology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text Free
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Westwood, F. R.
Right arrow Articles by Scott, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westwood, F. R.
Right arrow Articles by Scott, R. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Toxicologic Pathology, Vol. 33, No. 2, 246-257 (2005)
DOI: 10.1080/01926230590908213


Articles

Statin-Induced Muscle Necrosis in the Rat: Distribution, Development, and Fibre Selectivity

F. Russell Westwood, Alison Bigley, Kevin Randall, Alan M. Marsden and Robert C. Scott

Safety Assessment, AstraZeneca, Macclesfield, Cheshire, SK10 4TG, United Kingdom

Correspondence: Address correspondence to: F. Russell Westwood, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom; e-mail:russell.westwood{at}astrazeneca.com

Simvastatin and cerivastatin have been used to investigate the development of statin-induced muscle necrosis in the rat. This was similar for both statins and was treatment-duration dependent, only occurring after 10 days had elapsed even if the dose was increased, and still occurring after this time when dosing was terminated earlier as a result of morbidity. It was then widespread and affected all areas of the muscular system. However, even when myotoxicity was severe, particular individual muscles and some types of fibres within affected muscles were spared consistently. Fibre typing of spared muscles and of acutely necrotic fibres within affected muscles indicated a differential fibre sensitivity to statin-induced muscle necrosis. The fibres showed a necrotic response to statin administration that matched their oxidative/glycolytic metabolic nature: Least sensitive ->I {leftrightarrow} IIA {leftrightarrow} IID {leftrightarrow} IIB <- most sensitive. Type I and IIB fibres represent metabolic extremes of a continuum of metabolic properties through the fibre types with type I fibres most oxidative in metabolism and type IIB fibres most glycolytic. In addition, in some (nonnecrotic) glycolytic fibres from muscles showing early multifocal single fibre necrosis the only subcellular alterations present in isolation of any other changes were mitochondrial. These changes were characterised by an increased incidence of vacuolation and the formation of myelinoid vesicular bodies that accumulated in the subsarcolemmal areas. These findings suggest an important early involvement of mitochondria in selective glycolytic muscle fibre necrosis following inhibition of the enzyme HMG-CoA reductase.

Key Words: Statin • muscle • necrosis • rat • development • type • fast-twitch • slow-twitch


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Toxicol SciHome page
M. L. Pritt, D. G. Hall, J. Recknor, K. M. Credille, D. D. Brown, N. P. Yumibe, A. E. Schultze, and D. E. Watson
Fabp3 as a Biomarker of Skeletal Muscle Toxicity in the Rat: Comparison with Conventional Biomarkers
Toxicol. Sci., June 1, 2008; 103(2): 382 - 396.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. A. Dykens, J. D. Jamieson, L. D. Marroquin, S. Nadanaciva, J. J. Xu, M. C. Dunn, A. R. Smith, and Y. Will
In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone
Toxicol. Sci., June 1, 2008; 103(2): 335 - 345.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. S. Madsen, E. Janovitz, R. Zhang, Van Nguyen-Tran, C. S. Ryan, X. Yin, H. Monshizadegan, M. Chang, C. D'Arienzo, S. Scheer, et al.
The Guinea Pig as a Preclinical Model for Demonstrating the Efficacy and Safety of Statins
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 576 - 586.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
F. R. Westwood, R. C. Scott, A. M. Marsden, A. Bigley, and K. Randall
Rosuvastatin: Characterization of Induced Myopathy in the Rat
Toxicol Pathol, February 1, 2008; 36(2): 345 - 352.
[Abstract] [Full Text] [PDF]